Coggrave M, Wiesel P H, Norton C
Stoke Mandeville Hospital, National Spinal Injuries Centre, Mandeville Road, Aylesbury, Buckinghamshire, UK, HP21 8AL.
Cochrane Database Syst Rev. 2006 Apr 19(2):CD002115. doi: 10.1002/14651858.CD002115.pub3.
People with neurological disease have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine line between the two conditions, with any management intended to ameliorate one risking precipitating the other. Bowel problems are observed to be the cause of much anxiety and may reduce quality of life in these people. Current bowel management is largely empirical with a limited research base.
To determine the effects of management strategies for faecal incontinence and constipation in people with neurological diseases affecting the central nervous system.
We searched the Cochrane Incontinence Group Specialised Trials Register (searched 26 January 2005), the Cochrane Central Register of Controlled Trials (Issue 2, 2005), MEDLINE (January 1966 to May 2005), EMBASE (January 1998 to May 2005) and all reference lists of relevant articles.
All randomised or quasi-randomised trials evaluating any types of conservative or surgical measure for the management of faecal incontinence and constipation in people with neurological diseases were selected. Specific therapies for the treatment of neurological diseases that indirectly affect bowel dysfunction were also considered.
Two reviewers assessed the methodological quality of eligible trials and two reviewers independently extracted data from included trials using a range of pre-specified outcome measures.
Ten trials were identified by the search strategy, most were small and of poor quality. Oral medications for constipation were the subject of four trials. Cisapride does not seem to have clinically useful effects in people with spinal cord injuries (three trials). Psyllium was associated with increased stool frequency in people with Parkinson's disease but did not alter colonic transit time (one trial). Prucalopride, an enterokinetic did not demonstrate obvious benefits in this patient group (one study). Some rectal preparations to initiate defaecation produced faster results than others (one trial). Different time schedules for administration of rectal medication may produce different bowel responses (one trial). Mechanical evacuation may be more effective than oral or rectal medication (one trial). There appears to be a benefit to patients in one-off educational interventions from nurses. The clinical significance of any of these results is difficult to interpret.
AUTHORS' CONCLUSIONS: There is still remarkably little research on this common and, to patients, very significant condition. It is not possible to draw any recommendation for bowel care in people with neurological diseases from the trials included in this review. Bowel management for these people must remain empirical until well-designed controlled trials with adequate numbers and clinically relevant outcome measures become available.
与普通人群相比,神经系统疾病患者发生大便失禁和便秘的风险要高得多。这两种情况之间往往界限很细微,任何旨在改善其中一种情况的治疗措施都可能引发另一种情况。据观察,肠道问题会引发诸多焦虑情绪,并可能降低这些患者的生活质量。目前的肠道管理方法大多基于经验,相关研究基础有限。
确定针对影响中枢神经系统的神经系统疾病患者的大便失禁和便秘管理策略的效果。
我们检索了Cochrane尿失禁小组专业试验注册库(检索日期为2005年1月26日)、Cochrane对照试验中央注册库(2005年第2期)、MEDLINE(1966年1月至2005年5月)、EMBASE(1998年1月至2005年5月)以及所有相关文章的参考文献列表。
选取所有评估针对神经系统疾病患者大便失禁和便秘的任何类型保守或手术治疗措施的随机或半随机试验。还考虑了用于治疗间接影响肠道功能障碍的神经系统疾病的特定疗法。
两名评价员评估符合条件试验的方法学质量,另外两名评价员使用一系列预先指定的结局指标,独立从纳入试验中提取数据。
检索策略共识别出10项试验,大多数试验规模较小且质量较差。有4项试验以治疗便秘的口服药物为研究对象。西沙必利似乎对脊髓损伤患者没有临床有用的效果(3项试验)。在帕金森病患者中,车前草与排便频率增加有关,但未改变结肠运输时间(1项试验)。普芦卡必利,一种促肠动力药,在该患者群体中未显示出明显益处(1项研究)。一些用于启动排便的直肠制剂比其他制剂产生更快的效果(1项试验)。直肠给药的不同时间安排可能产生不同的肠道反应(1项试验)。机械排便可能比口服或直肠用药更有效(1项试验)。护士进行的一次性教育干预似乎对患者有益。这些结果中任何一项的临床意义都难以解读。
对于这种常见且对患者非常重要的情况,目前的研究仍然非常少。从本综述纳入的试验中无法得出针对神经系统疾病患者肠道护理的任何建议。在有足够数量且具有临床相关结局指标的精心设计的对照试验出现之前,这些患者的肠道管理必须继续基于经验。